Welcome to our dedicated page for SERA PROGNOSTICS SEC filings (Ticker: SERA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sera Prognostics, Inc. filings document a public women's health diagnostics company focused on pregnancy biomarker information and the PreTRM® Test. Recent 8-K reports furnish quarterly and annual financial results, business highlights, investor presentations and Regulation FD disclosures tied to PRIME study publications and PreTRM clinical evidence.
Its proxy materials describe annual meeting matters, corporate governance, shareholder voting items, strategic priorities, capital allocation and commercial progress. The filing record also covers securities-law treatment of furnished press releases and exhibits related to results, clinical data and market-adoption updates.
SERA PROGNOSTICS, INC. officer Paul Kearney, Chief Data Officer, filed a Form 4 reporting no insider trading activity. The filing shows no reported purchases, sales, option exercises, gifts, tax withholdings, or other equity transactions, and no derivative positions listed for this period.
SERA PROGNOSTICS, INC. executive Harrison Robert Gardner, the Chief Information Officer, filed a Form 4 insider report. The provided data shows no reported purchases, sales, gifts, exercises, or other share transactions, and no derivative positions or holdings are listed in this filing.
SERA PROGNOSTICS, INC. filed a Form 4 for Chief Scientific Officer John J. Boniface. The filing shows no reported purchases, sales, gifts, exercises, or other insider transactions, with all transaction counts and share amounts listed as zero in the summary data.
Sera Prognostics reported another early-stage quarter with very limited revenue and ongoing losses while highlighting a strong cash position and cost-cutting plans. For the three months ended March 31, 2026, revenue was $14 thousand, down from $38 thousand, and net loss was $8.4 million, or $0.17 per share.
Total assets were $93.5 million, including $4.2 million in cash and equivalents and $82.6 million in marketable securities, with stockholders’ equity of $67.6 million. The company is refocusing from research to commercialization of its PreTRM test, cutting about 18% of its workforce and expecting roughly $1.3 million in severance costs and about $9.6 million in 2027 cost savings. Management believes existing liquidity can fund operations through 2029.
Sera Prognostics, Inc. reported first quarter 2026 results, showing it remains in an early commercial stage while emphasizing extended financial runway. Revenue was $14,000 versus $38,000 a year earlier, reflecting limited commercial adoption of its PreTRM test so far.
Total operating expenses were $9.4 million, with $3.0 million in research and development and $6.3 million in selling, general and administrative costs as the company invests in commercialization. Net loss was $8.4 million, or $0.17 per share, similar to the prior-year loss.
As of March 31, 2026, Sera held about $86.8 million in cash, cash equivalents and marketable securities and expects this to fund operations through 2029 after a business review that shifted spending from clinical work toward reimbursement-driven commercialization. The company highlighted new clinical evidence for its PreTRM test, growing clinician engagement, payer discussions across 15 states and progress toward CE marking in Europe.
Sera Prognostics reports amended Schedule 13G ownership by Whetstone Capital Advisors, LLC and David Atterbury. The filing states the Reporting Persons beneficially own 3,306,889 shares of Class A Common Stock, representing 8.6% of the class. The signature dates are 05/01/2026.
Sera Prognostics, Inc. is asking stockholders to vote at its virtual 2026 Annual Meeting on June 4, 2026 to elect three Class II directors for terms through 2029 and to ratify Ernst & Young LLP as independent auditor for 2026, along with other routine business. The proxy highlights progress on the company’s PreTRM® pregnancy blood test, including the PRIME Study of 5,018 women, which reported 56% and 32% fewer births before 32 and 35 weeks, 20% fewer NICU admissions, lower neonatal morbidity, and one NICU day saved per 4.2 patients screened. The company reports expanded U.S. commercial engagement with payers across 13 states, leadership hires in commercial and medical roles, and work toward CE marking for a global PreTRM test in Europe. It also notes a February 2025 underwritten public offering of common stock and pre-funded warrants that generated approximately $57.5 million in gross proceeds, extending its cash runway through 2028. Governance features include a majority‑independent, staggered board, separated chair and CEO roles, fully independent key committees, a clawback policy, strict anti‑hedging rules, and a compensation program tying a significant portion of executive pay to clinical, commercial, and financial performance.
Robert Harrison filed a Form 144 notice relating to proposed sales of Common stock for SERA. The filing lists 2,000 Restricted Stock Units dated 08/06/2024 and records multiple 10b5-1 sales earlier in 2026 with specific dates and share counts.
SERA insider Robert Harrison reported multiple sales of Common Stock under Form 144. The filing lists sales on 03/11/2026 (716 shares, 1460.64), 03/09/2026 (3,360 shares, 6585.60), 02/24/2026 (2,000 shares, 4686.00), 01/27/2026 (2,000 shares, 5942.00), and 12/30/2025 (2,000 shares, 6002.60). Several sales are labeled as 10b5-1 Sales. The filing also lists 2,000 Restricted Stock Units dated 02/06/2024.